Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension

Journal of Human Hypertension volume 23, pages 420–425 (2009)Cite this article

Abstract

This study was conducted to assess the use of angiotensin receptor blockers (ARBs) in European paediatric patients experiencing essential hypertension. This was a retrospective analysis of the IMS MIDAS Prescribing Insight Medical Database. Five major important European markets, including France, Germany, Italy, Spain and the UK were studied for the usage of ARBs as either a monotherapy or fixed-dose combination (FDC) therapy . Paediatric patients with essential hypertension were identified using ICD-10 codes, and anatomical therapeutic chemical (ATC) classification was used to identify major classes of antihypertensives. Projected prescription data for paediatric patients (<18 years) in the time period of October 2005 to September 2006 were analysed. Special emphasis was placed on the category of 6–17 years of age, as many ARBs were recommended in children above 6 years of age. Out of 242 405 estimated paediatric patients with hypertension, 222 033 (91.6%) were diagnosed with essential hypertension. Out of 230 220 projected prescriptions dispensed in these essential hypertensives, approximately 76.2% were for patients in the category of 6–17 years of. In the age group of 6–17 years, ARBs constituted 25.5% of the projected prescriptions, with 10.6% in the form of FDC of ARBs with hydrochlorothiazides (HCTz). Projected ARB prescription usage, either as a monotherapy or as an FDC with HCTz, was higher in Italy (35.7%), France (30.9%) and Spain (28.1%), but was lower in Germany (5.3%), and non-existent in the United Kingdom. Valsartan-based and losartan-based FDCs were commonly used in the age range of 6–17 years, and accounted for 39. and 13.9% of the projected prescription volume in the ARB–FDC category, respectively. In a majority of the important European markets, paediatric hypertensive patients in the age range of 6–17 years are often treated with ARB monotherapy or FDC therapy. Some ARBs lack necessary clinical studies to support its use in treating essential hypertension in paediatric patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369.

    Article  PubMed  Google Scholar 

  2. Health in the European Union. Special Eurobarometer ( http://ec.europa.eu/health/ph_publication/eb_health_en.pdf. Last accessed 07/07/08), 1-52. 2007. Ref Type: Electronic Citation.

  3. Antikainen R, Jousilahti P, Tuomilehto J . Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. J Hypertens 1998; 16: 577–583.

    Article  CAS  PubMed  Google Scholar 

  4. O’Donnell CJ, Ridker PM, Glynn RJ, Berger K, Ajani U, Manson JE et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation 1997; 95: 1132–1137.

    Article  PubMed  Google Scholar 

  5. Trenkwalder P, Hendricks P, Schoniger R, Rossberg J, Lydtin H, Hense HW . Hypertension as a risk factor for cardiovascular morbidity and mortality in an elderly German population; the prospective STEPHY II study. Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly. Eur Heart J 1999; 20: 1752–1756.

    Article  CAS  PubMed  Google Scholar 

  6. Zanchetti A, Hansson L, Dahlof B, Elmfeldt D, Kjeldsen S, Kolloch R et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19: 1149–1159.

    Article  CAS  PubMed  Google Scholar 

  7. Mitsnefes MM . Hypertension in children and adolescents. Pediatr Clin North Am 2006; 53: 493–512.

    Article  PubMed  Google Scholar 

  8. Varda NM, Gregoric A . A diagnostic approach for the child with hypertension. Pediatr Nephrol 2005; 20: 499–506.

    Article  PubMed  Google Scholar 

  9. Flynn JT . Evaluation and management of hypertension in childhood. Prog Pediatr Cardiol 2001; 12: 177–188.

    Article  PubMed  Google Scholar 

  10. Coody DK, Yetman RJ, Portman RJ . Hypertension in children. J Pediatr Health Care 1995; 9: 3–11.

    Article  CAS  PubMed  Google Scholar 

  11. Pinto A, Roldan R, Sollecito TP . Hypertension in children: an overview. J Dent Educ 2006; 70: 434–440.

    PubMed  Google Scholar 

  12. Luma GB, Spiotta RT . Hypertension in children and adolescents. Am Fam Physician 2006; 73: 1558–1568.

    PubMed  Google Scholar 

  13. Chiolero A, Madeleine G, Gabriel A, Burnier M, Paccaud F, Bovet P . Prevalence of elevated blood pressure and association with overweight in children of a rapidly developing country. J Hum Hypertens 2007; 21: 120–127.

    Article  CAS  PubMed  Google Scholar 

  14. Chiolero A, Cachat F, Burnier M, Paccaud F, Bovet P . Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens 2007; 25: 2209–2217.

    Article  CAS  PubMed  Google Scholar 

  15. Schiel R, Beltschikow W, Kramer G, Stein G . Overweight, obesity and elevated blood pressure in children and adolescents. Eur J Med Res 2006; 11: 97–101.

    CAS  PubMed  Google Scholar 

  16. Friedman AL . Approach to the treatment of hypertension in children. Heart Dis 2002; 4: 47–50.

    Article  PubMed  Google Scholar 

  17. Robinson RF, Nahata MC, Batisky DL, Mahan JD . Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs 2005; 7: 27–40.

    Article  PubMed  Google Scholar 

  18. Novartis Garners Pediatric Exclusivity for Diovan. FDAnews Drug Daily Bulletin ( http://www.fdanews.com/newsletter/article?articleId=97384&issueId=10606Last Accessed 07/07/2008) 4[163]. 7 A.D. Ref Type: Electronic Citation.

  19. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–576.

  20. Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason Jr C et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007; 161: 282–290.

    Article  PubMed  Google Scholar 

  21. Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 2007; 29: 361–367.

    Article  PubMed  Google Scholar 

  22. Yoon EY, Dombkowski KJ, Rocchini A, Lin JJ, Davis MM . Off-label utilization of antihypertensive medications in children. Ambul Pediatr 2007; 7: 299–303.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Livermore DM, Reynolds R, Stephens P, Duckworth G, Felmingham D, Johnson AP et al. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Int J Antimicrob Agents 2006; 28: 273–279.

    Article  CAS  PubMed  Google Scholar 

  24. Wong IC, Murray ML, Camilleri-Novak D, Stephens P . Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child 2004; 89: 1131–1132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wong IC, Murray ML . The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005; 59: 750–755.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Arar MY, Hogg RJ, Arant Jr BS, Seikaly MG . Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol 1994; 8: 186–189.

    Article  CAS  PubMed  Google Scholar 

  27. Hanna JD, Chan JC, Gill Jr JR . Hypertension and the kidney. J Pediatr 1991; 118: 327–340.

    Article  CAS  PubMed  Google Scholar 

  28. Blowey DL . Safety of the newer antihypertensive agents in children. Expert Opin Drug Saf 2002; 1: 39–43.

    Article  CAS  PubMed  Google Scholar 

  29. Sadowski RH, Falkner B . Hypertension in pediatric patients. Am J Kidney Dis 1996; 27: 305–315.

    Article  CAS  PubMed  Google Scholar 

  30. Bianchetti MG, Ammenti A, Avolio L, Bettinelli A, Bosio M, Fossali E et al. Prescription of drugs blocking the renin-angiotensin system in Italian children. Pediatr Nephrol 2007; 22: 144–148.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Practice and Administration, College of Pharmacy, The Ohio State University, Columbus, OH, USA

    R Balkrishnan & S Karve

  2. Merck and Co. Inc., Whitehouse Station, NJ, USA

    H Phatak & G Gleim

Authors
  1. R Balkrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Phatak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Gleim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Karve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Balkrishnan.

Appendix 1

Appendix 1

Table A1

Table a1 Important features of MAS MIDAS prescribing insight database across five major European countries
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balkrishnan, R., Phatak, H., Gleim, G. et al. Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension. J Hum Hypertens 23, 420–425 (2009). https://doi.org/10.1038/jhh.2008.139

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2008.139

Keywords

This article is cited by

Search

Advanced search

Quick links